Transdermal rotigotine for the perioperative management of Parkinson’s disease

Continuous delivery of antiparkinsonian medication during a perioperative period is desirable to avoid ‘off’-symptom complications in surgical patients with concomitant Parkinson’s disease (PD). Fourteen PD patients undergoing surgery under general anesthesia were switched from oral dopaminergic med...

Descripción completa

Detalles Bibliográficos
Autores principales: Wüllner, Ullrich, Kassubek, Jan, Odin, Per, Schwarz, Michael, Naumann, Markus, Häck, Hermann-Josef, Boroojerdi, Babak, Reichmann, Heinz
Formato: Texto
Lenguaje:English
Publicado: Springer Vienna 2010
Materias:
Movement Disorders - Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895903/
https://www.ncbi.nlm.nih.gov/pubmed/20535621
http://dx.doi.org/10.1007/s00702-010-0425-4
Descripción
Sumario:Continuous delivery of antiparkinsonian medication during a perioperative period is desirable to avoid ‘off’-symptom complications in surgical patients with concomitant Parkinson’s disease (PD). Fourteen PD patients undergoing surgery under general anesthesia were switched from oral dopaminergic medication to transdermally delivered 24-h rotigotine (median dose 12 mg/24 h) for the perioperative period. Rotigotine treatment was considered feasible by patients, their anesthesiologists and neurologists with good control of PD symptoms and easy switching and re-switching of PD medication.

Ejemplares similares